Health & Safety Industry Today

Rheumatoid Arthritis Drugs Market - Segmented by Type of Molecule, Drug Class, Sales Channel, and Geography - Growth, Trends, and Forecast (2018 - 2023)

The global rheumatoid arthritis drugs market is expected to register a CAGR of 10.5% during the forecast period of 2018-2023.
Published 26 July 2018

Rheumatoid Arthritis (RA) is an auto-immune disease that can cause joint pain and damage all over the body. As per the estimates of the World Health Organization (WHO), the prevalence varies between 0.3% and 1%, and it is more common in women and developed countries. Factors, such as the influx of new biopharmaceuticals, growing patient awareness of RA, and increasing prevalence of arthritis are expected to fuel the market’s growth, over the forecast period. Owing to the rise in the adoption of sedentary lifestyle, the patient pool in Asia-Pacific is expected to witness healthy growth. Therefore, Asia-Pacific is expected to emerge as the fastest growing segment of the market studied.

Request sample copy of Rheumatoid Arthritis Drugs Market report at:

Rise in the Prevalence of Arthritis

The major risk factors associated with the onset of rheumatoid arthritis are - genetics, environmental factors, hormones, and sedentary lifestyles. According to the estimates of the Centre for Disease Control and Prevention, during 2013-2015, an estimated 54.4 million US adults (about 22.7%) annually, were diagnosed with some form of arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia.

Other factors, such as growing geriatric population and increasing acceptance of biopharmaceuticals are expected to drive the growth of the market studied, over the forecast period.

Read details of the report at:

Alternative Treatment Options

The alternative treatment options, such as acupuncture, physical therapy, and occupational therapy are expected to hamper the market’s growth. Most of the patients prefer medications related to rheumatoid arthritis. However, medications are not quite effective against RA. Therefore, most of the patients suffering from RA are opting for the above-mentioned alternative therapies.

The other factor that acts as a restraint for the market studied is the patent expiration of blockbuster drugs of rheumatoid arthritis.

North America to Dominate the Market

North America dominates the global rheumatoid arthritis drugs market. The dominance of the region can be attributed to factors, such as ease of access to healthcare facilities, favorable reimbursement policies, robust clinical pipeline, and speedy approval of novel drugs. In addition, owing to increasing adoption of sedentary lifestyle, growing geriatric population, and immunological disorders, the region is experiencing a rise in the prevalence of rheumatoid arthritis. According to estimates of the Centre for Disease Control and Prevention (CDC) by 2040, about 78 million (26%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis. Hence, the aforementioned factors are expected to drive the growth of the North American segment of the market studied, over the forecast period.

Key Developments in the Market

May 2018 - Sandoz, a Novartis division, announced that the European Commission (EC) has approved Zessly (infliximab) for use in Europe.

December 2017 - AbbVie's Upadacitinib demonstrated positive results as monotherapy in phase 3 rheumatoid arthritis study, meeting all primary and key secondary endpoints.


Reasons to Purchase this Report

  • Current and future global rheumatoid arthritis drugs market outlook in the developed and emerging markets
  • Analysis of various perspectives of the market, with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3 months analyst support, along with the Market Estimate sheet (in excel)

Customization of the report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure that you to get a report that suits your needs.

Companies Mentioned:

AbbVie Inc., Amgen Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche AG, Johnson & Johnson Services Inc., Merck & Co. Inc., and Novartis AG

Enquire more details of the report at:

About Us:

Orbis Research ( is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:

Hector Costello

Senior Manager – Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas – 75204, U.S.A.

Phone No.: +1 (214) 884-6817; +91641010

Other Industry News

Ready to start publishing

Sign Up today!